Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases,  announced the closing of a $40M Series A financing round.

The round was led by Khosla Ventures and Ahren Innovation Capital, with ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, unveiled Cell Q™, the first automated quality control (QC) workcell for cell therapy manufacturing. Cell Q™ addresses a critical challenge.

The ...

CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of a new line of cryogenic multi-use dewars for the cell and gene therapy market. The progressive technology, which is the first in CSafe's CGT Cryo ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin Acetate) approved by the U.S.

Food and ...

Fresenius, via its operating company Fresenius Kabi, announced the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.

Michael Sen, ...

Can-Fite BioPharma a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced that Biomedicines published an article titled “Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis (MASH) ...